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Introduction
Adenoviral vectors are attractive candidates for gene transfer to the central nervous system (CNS), as they can infect a very broad host range including quiescent and terminally differentiated cells such as neurons. Moreover, as adenoviral vectors can be prepared at high titre, this enables gene transfer to be effective even when small volumes are delivered to the target tissue. Since the intracranial and intracerebroventricular space have limited extracellular capacity, gene delivery in small volumes is highly desirable.
Transgene expression following gene therapy using recombinant adenovirus is transient in most in vivo systems. Effective gene transfer and expression in the lung, 1, 2 liver, 3, 4 muscle, 5 and brain [6] [7] [8] [9] is limited by cellular and humoral immune responses triggered following administration of adenoviral vectors. The cytokines IFN-gamma and TNF-alpha produced during the immune response have been shown to inhibit transgene expression from viral promoters. [10] [11] [12] [13] In addition, cytotoxic T lymphocytes (CTL) and neutralizing antibodies are also likely to be involved in limiting the persistence of transgene expression. In certain situations it would be highly desirable to readminister the gene of interest. The production of neutralizing anti-adenovirus antibodies is likely to reduce the efficacy of repeated administration of adenoviral vectors. 14 In addition, as the majority of the human population has been exposed to adenovirus, these vectors in clinical settings may be severely compromised. 15 The brain is traditionally considered an immunologically privileged organ, as it is partly shielded from immune surveillance. Several factors contribute to its privileged status: the blood-brain barrier (BBB) reduces the level of lymphocyte traffic though the brain; the CNS lacks lymphatic capillaries; most of the cells of the brain, including neurons, astrocytes and oligodendrocytes, do not normally express any or only very low levels of MHC antigens 16 and there are no dendritic cells in normal brain parenchyma. 17 In contrast, in pathological conditions the presence of dendritic cells in the brain and the breakdown of BBB have been reported. 18, 19 In other organs, dendritic cells play a key role in initiating immune responses to cell-associated antigens. 20 Since there are marked immunological differences between the brain and other organs, it is difficult to extrapolate the immune consequences of adenoviral vector delivery to other tissue to that of brain. For example, the transgene expression from adenoviral vectors have been shown to persist in the brain in some studies. [21] [22] [23] [24] In a previous study we showed the persistence of adenoviral vectors and the transgene expression for at least 60 days after injection in spite of the presence of significant transient immune responses to the vector in the brain. 25 Although the inflammatory response in the brain was greatly diminished at this point, subcutaneous injection caused the recurrence of inflammation. 25 Thus previous immunological history may determine the outcome, both in terms of quality and duration of a subsequent immune response to a defined immunological challenge. The objective of this study was to investigate the effects of both environmental pathogens and specific immunological priming to a single agent, adenovirus, on the evolution of subsequent immune responses following adenovirus delivery to the brain. This information is necessary to identify and optimize strategies for gene delivery using adenoviral vectors that will have reduced immunological problems.
Results
Influence of priming First we compared the kinetics and magnitude of the immune response to adenovirus (AdLacZ) injected into the brains of either unprimed C3H.He (H-2 k ) and C57BL/6J (H-2 b ) mice, or mice previously sensitized to adenovirus in the periphery. AdLacZ was injected into the striatum at either a single site (1 × 10 6 p.f.u.) for analysis of the infiltrating leucocytes by immunohistochemistry or at four sites (2 × 10 7 p.f.u.) for quantification and phenotypic analysis of the infiltrating leucocytes by FACS analysis.
In both primed and unprimed mice injection of AdLacZ into the brain at either a single or multiple sites resulted in a rapid inflammatory response and leucocyte infiltration into the brain (Figures 1, 2 and 3) . Analysis of the brains from primed and unprimed C3H and C57BL/6 mice by immunohistochemistry at 9 and 30 days after intracranial injection showed higher numbers of leucocytes (CD45 + ) present in the brains of the primed mice in both cases (Figure 1a and b) . The number of T cells (CD3 + ) present in the brains for primed mice was also higher than in unprimed mice. Interestingly, in primed mice CD8 + T cells were the dominant subset, whereas in naive mice CD4 + T cells were present in greater numbers 9 days after delivery of AdLacZ to the brain (Figure 1c and d versus e and f).
FACS analysis was performed to quantify the magnitude of the immune response in both strains; data for C3H mice are shown in Figures 2 and 3 . The number of CD45 + cells recovered from the brains of C3H mice previously primed to adenovirus was significantly higher than the number isolated from the brains of unprimed mice (Figure 2 
Within the CD45
+ leucocyte infiltrate the proportion of CD3 + T cells was higher in the brains of mice previously sensitized to adenovirus at both 9 and 30 days after injection of AdLacZ (Figure 3 ; 68.5 ± 6.2%, P Ͻ 0.01 at 9 days; 45.8 ± 4.7, P Ͻ 0.05 at 30 days compared with 42.9 ± 3.8 at 9 days, 25.6 ± 6.4 at 30 days per brain in primed and unprimed mice). Within the T cell population the proportion of CD4 + and CD8 + T cells was markedly different when primed and unprimed mice were compared. In the primed mice CD8 + T cells were dominant whereas in unprimed mice the CD4
+ subset was present in higher numbers ( Figure 3 ; %CD8 + T cells; 38.4 ± 4.5, P Ͻ 0.01 at 9 days; 26.8 ± 5.1, P Ͻ 0.05 at 30 days compared with 15.0 ± 0.9 at 9 days, 9.8 ± 3.4 at 30 days per brain in primed and unprimed mice).
Antibody production to the adenovirus virion ( Figure   4a ) and the ␤-galactosidase transgene (Figure 4b ) could be detected in serum after inoculation of adenovirus vectors in the brain in both primed and unprimed mice. Anti-adenovirus and anti-␤-galactosidase antibody titres in the serum of unprimed C3H mice did not change markedly between the two time-points analyzed day 9 and day 30 ( Figure 4a ). In sensitized mice, antibody production to the adenovirus back bone was considerably higher as expected ( Figure 4a ). Antibody production to the transgene was also higher in the primed mice ( Figure  4a ; 320.7 ± 24.6 at 9 days, P Ͻ 0.005 compared with 120.7 ± 34.5 at 9 days per brain in primed and unprimed mice; Figure 4b ; 62.7 ± 19.0 at 30 days, P Ͻ 0.05 compared with 9.7 ± 2.7 at 30 days per brain in primed and unprimed mice). The kinetics of production of anti-adenovirus antibody and anti-ß-galactosidase antibody were different in both situations. The production of anti-␤-galactosidase antibody was correlated with diminution of ␤-galactosidase expression in the brain (see Figure 8 ).
Influence of genetic background and environmental conditions Next the influence of two further parameters, genetic background and environmental conditions on the immune response to AdLacZ injected into the brain were first 30 days after inoculation. In contrast, antibody responses to either the vector or the transgene in mice housed under SPF conditions were virtually undetectable at day 9 ( Figure 5a and b, Figure 6b ).
Anti-adenovirus and anti-␤-galactosidase responses were consistently higher in mice of either strain housed under conventional conditions. Responses to both adenovirus and the transgene were higher in C3H mice compared with C57BL/6 mice ( Figures 5 and 6 ). These observations were statistically significant (anti-adenovirus antibody titres; conventional C3H versus SPF C3H, P Ͻ 0.0001 at 9 days, P Ͻ 0.05 at 30 days; conventional C57BL/6 versus SPF C57BL/6, P Ͻ 0.0001 at 9 days). Surprisingly, even though mice had been primed to the vector, antibody responses to adenovirus and ␤-galactosidase were consistently higher in mice of either strain housed under conventional conditions; data for antiadenovirus antibody titres in C3H mice are shown in Figure 7 (primed conventional C3H versus primed SPF C3H, P Ͻ 0.0001 at 9 days).
At 9 days, high ␤-galactosidase expression was seen in the striatum, corpus callosum and ependymal cells of the ventricle in unprimed mice housed under SPF conditions (Figure  8e and f). The positive cells in the corpus callosum and ventricular ependymal cells were due to leakage of vectors from the injection site. We also detected ␤-galactosidase expression in the neurons of the ipsilateral substantia nigra pars compacta (SNc) which sends afferent projections to the striatum (data not shown). Mice housed in SPF facilities exhibited prolonged transgene expression compared with conventional mice housed under conventional conditions (Figure 8c and g ). In primed mice housed under all conditions, ␤-galactosidase expression rapidly declined at 9 days (Figure 8d ) and transgene expression could not be detected at 30 days (Figure 8h ). There was no distinct difference in ␤-galactosidase expression between C3H and C57BL/6 mice ( Figure 8a and e versus b and f).
Discussion
The administration of adenoviral vectors even to the a relatively immunological privileged site such as the brain induces less inflammatory response than in peripheral organs. [6] [7] [8] [9] An immune response is triggered and although this does not result in such a rapid loss of transgene expression as has been reported after adenoviral gene transfer to other organs, such as the lung or liver, [1] [2] [3] [4] it compromises the effectiveness of gene delivery to the brain. Different strategies to overcome the immunogenicity of adenoviral vectors are being investigated. These include reengineering the vector both to remove the most immunogenic components [26] [27] [28] [29] [30] [31] and adding genes with immunomodulating potential 32, 33 as well as treating recipients with immunosuppressive drugs 34, 35 and molecules at the time of gene transfer.
36-38
The majority of experimental studies using adenoviral vectors are performed under controlled environmental conditions in the absence of pathogens; conditions that may be unrepresentative of a normal human environment. It is therefore critical to evaluate the immunolog- ical consequences of previous adenovirus and other infections on the efficacy of gene delivery at the site of interest under relevant environmental conditions as cross priming and bystander activation of the immune system may affect gene expression. To address some of these issues we have investigated the effects of sensitization to adenovirus, environmental conditions and genetic background on the immune response to adenoviral vectors used to deliver genes to the brain.
Primary infection with an adenovirus usually takes place in the first few years of life and most people have been infected with one or more adenovirus serotypes. 15 It is therefore important to consider the effect previous adenovirus infections would have on the efficacy of gene therapy using adenoviral vectors. Virus-specific CD8 + cytotoxic T cells (CTL) are traditionally thought to be the effector cells in the control and elimination of viral infections. While this is true for some viruses, such as lymphocytic choriomeningitis virus and the murine gammaherpesvirus 68, [39] [40] [41] for others, such as influenza virus infection of the murine respiratory tract, both CD4 + and CD8 + T cells are involved. [42] [43] [44] In this study the prevalence of CD4 + and CD8 + T cells in the brain after injection of an adenoviral vector was evaluated in primed and unprimed mice by both immunohistology and FACS analysis (Figures 1, 2 and 3 ). To enable both methods of analysis to be used two protocols were used for vector delivery to the right striatum. For immunohistochemistry a single injection of 1 × 10 6 p.f.u. (0.5 or 1 l) was used and for isolation of brain infiltrating leucocytes multiple injections of 2 × 10 7 p.f.u. (1 l per site) were used to enable isolation of a sufficient number of cells for FACS analysis. We confirmed that the magnitude of the infiltrate was related to virus dose and that the composition of the infiltrate was not affected (Ohmoto et al, unpublished observations). In this study ␤-galactosidase-positive cells were observed in the corpus callosum and ventricular ependymal cells when either 0.5 or 1 l of adenoviral vector was injected at a single site into the right striatum using stereotactic guidance ( Figure  8 ). It has been shown by Stevenson and colleagues 45 that the brain parenchyma and cerebral ventricules are treated as different compartments by the immune system. Antibody responses were not detected when influenza virus was used to infect brain parenchyma whereas an immune response was detected when virus was delivered to the lateral ventricle (injection volume 0.5 l). Thus, in our study we cannot rule out the possibility that there was leakage of vector after injection into the striatum.
The data obtained in this study show that CD4 + and CD8 + T cells play a role in the response to adenoviral vectors in the brain (Figures 2 and 3) and that previous sensitization to adenovirus increased the magnitude of the immune response both in the brain (Figures 1, 2 and  3) . Interestingly, in naive mice CD4 + T cells were present in higher numbers in the leukocyte infiltrate in the brain 9 days after injection (Figure 3a) , whereas in mice previously sensitized to adenovirus in the periphery CD8 + T cells dominated the response at day 9 (Figure 3b ). These data suggest that the two T subsets may play a differential role in primary and secondary immune responses and importantly that it may be necessary to use different forms of immunosuppressive therapy targeting a different T cell subset in primed and sensitized individuals.
The involvement of CD4 + T cells in the response to adenoviral vectors in naive mice is not too surprising. CD4 + T cells have been shown by others to contribute to the elimination of adenovirus-transduced hepatocytes in vivo. 46 Moreover, it has been shown by our laboratory that treatment with monoclonal antibodies specific for CD4 can inhibit the immune response following intracranial injection of adenoviral vectors in naive mice. 7 In contrast, in sensitized hosts the more rapid infiltration of CD8 + T cells into the brain (Figure 3b ) is most likely to be a consequence of enhanced CTL responses due to T cell memory. [47] [48] [49] Therefore, sensitization with adenoviral vectors before brain inoculation might elevate CTL precursor frequency in lymphoid organs. In other systems the use of different immunosuppressive agents has been shown to be necessary to control the immune response in naive and sensitized recipients. 50 More work is required to explore and compare the efficacy of different immunomodulating and immunosuppressive agents in controlling the immune response following delivery of adenoviral vectors to the brain in naive and sensitized hosts.
Little attention has been given in previous studies exploring the immunological consequences of gene transfer to the importance of environmental conditions on the character of immune response that develops. For example, viral infections can result in intense activation of the immune system resulting in a dramatic increase in the total number of leukocytes present in the peripheral lymphoid organs. 51 In addition to an increase in the number of virus-specific T cells the number of alloreactive and antigen cross reactive T cells has also been shown to increase. 52, 53 Moreover, during the acute phase of the immune response to a viral infection most T cells show signs of activation and have altered expression of adhesion molecules suggesting that they may migrate differently in vivo. In this situation some of the T cells may have been activated in a bystander fashion. 54 Previously, these data were interpreted as indicating that some T cells may be activated in a bystander fashion following virus infection. Thus specific priming to a known virus and other infectious agents present in the environment might influence the outcome of a specific challenge. That this is the case has been shown in a model of a glomerulonephritis. Lule et al 55 showed that mice housed under conventional conditions developed higher intensity of Ig deposits in glomeruli than mice housed in part barrier facilities. Changing the environmental conditions can also affect the tempo and character of an immune response. For example transferring animals from germ-free to a conventional environment resulted in an increase in antibody production. 56 The interpretation of these and the findings reported here may need to be reinterpreted in the light of recent data using MHC class I tetramers to evaluate the frequency of virus-specific T cells in vivo. These studies have shown that the frequency of virus-specific T cells is much higher than originally anticipated from other methods of analysis and the majority of the T cells responding in an infected individual are virus-specific. 57, 58 It would be interesting to evaluate whether this was also the case after gene delivery using adenoviral vectors.
In the present study, irrespective of whether the mice had been deliberately primed to adenovirus, antibody responses to either the vector or the transgene were consistently lower in mice housed under SPF facilities compared with those housed under conventional conditions ( Figures 5, 6 and 7) . Thus, from these data, it is clear that B cell repertoire development was strongly affected by exogenous antigen present in the environment. In addition, the reduced inflammatory response following injection of adenoviral vectors into the brains of mice housed under SPF conditions (Figure 1 ) resulted in prolonged persistence of ß-galactosidase expression in the brain (Figure 8 ). Thus previous exposure to environmental pathogens can influence the immune response to adenoviral vectors delivered to the brain in both naive and mice previously sensitized to adenovirus.
Variation in the immune response between different strains of mice appears to be under multigenic control by both H-2-associated genes on chromosome 17 and non-H-2 genes on chromosome 11 and others. [59] [60] [61] This has a dramatic influence on the susceptibility to infection by a particular virus and on the persistence of transgene expression following gene transfer in vivo.
Thus both the nature of the virus and of the transgene contribute to the outcome of the response as demonstrated in this study. Mouse strains differ in their CTL response to adenovirus type 5. 62 Significantly higher CTL activity against adenoviral proteins was detected in vector-treated C57BL/6 mice compared with that of C3H. 63 In general, C57BL/6 mice produced lower amounts of antibodies for a given dose of antigen. 64 This observation was confirmed in our study; antibody titres in C3H mice were consistently higher than those of C57BL/6 mice ( Figures 5 and 6 ). C57BL/6 have been reported to exhibit a stable pattern of transgene expression of human factor IX (hFIX) and human alpha-1-antitrypsin (hAA). 59, 65 However, ␤-galactosidase expression in the brain was not significantly different between C3H.He and C57BL/6 mice in this study (Figure 8 ). ␤-galactosidase is highly immunogenic and induces a strong specific cellular and humoral responses, 66 whereas hFIX and hAA may be less immunogenic. In support of this hypothesis, although antibodies to hFIX could not be detected in C57BL/6 mice in the previous study, 67 antibodies to ␤-galactosidase were synthesized by C57BL/6 mice in this study (Figure 6b) .
In summary, this study clearly demonstrates that previous sensitization to adenovirus, environmental conditions, and genetic backgrounds will affect both the quality and duration of the immune response triggered 479 by gene delivery to the brain. Therefore, it will be important to explore the efficacy of the agent of choice under relevant conditions before clinical trials investigating gene delivery to the brain are undertaken.
Materials and methods

Adenoviral vectors
AdLacZ was an E1-deleted human adenovirus type 5 vector containing the lacZ gene (encoding ␤-galactosidase) under control of the RSV promoter. AdLacZ vector used in this study has been previously described. 6 The titre determined by plaque assay on 293 cells was 5 × 10 9 p.f.u./ml.
Animals and surgical procedures C3H.He and C57BL/6J mice were obtained from Harlan UK (Bicester, UK) and housed in either the conventional animal facility in the Department of Human Anatomy or the SPF animal facility in the Department of Pharmacology were used in this study. Mice were primed by injecting AdLacZ (5 × 10 7 p.f.u.) subcutaneously in the dorsal thorax 4 weeks before injection of AdLacZ into the brain. Primed and unprimed mice were maintained in each facility for 4 weeks to determine the influence of housing conditions (conventional or SPF conditions) on immune responses. Mice were 10 to 12 weeks of age at the time of the brain injection. Mice were anesthetized with ketamine and xylazine and immobilized in a stereotactic injection frame. Multiple injection sites: a total of 4.0 l (2 × 10 7 p.f.u.) AdLacZ vectors were injected into four sites (1.0 l into each site) in bilateral striatum (two sites in each side, from bregma: AP 0 mm and +1 mm, lateral 2 mm, vertical 2.5 mm) using a glass micropipette. Single injection site: mice were injected into right striatum (from bregma: AP 0 mm, lateral 2 mm, vertical 2.5 mm) with either 1 l or 0.5 l of adenoviral vector (1 × 10 6 p.f.u.) using a glass micropipette. Mice were killed at 9 and 30 days. Our previous work had shown that 9 days after brain inoculation is the peak time of the inflammation and that ␤-galactosidase expression in the brain is considerably diminished at 30 days. 6, 8 Isolation of inflammatory cells from brain Collagenase digestion of the brain followed by isolation of the inflammatory cells using a density gradient has been previously described by Kajiwara et al. 9 Flow cytometry Cells were incubated with 10% mouse serum for 15 min at 4°C before adding the primary antibodies for 45 min at 4°C. Rat anti-mouse primary antibodies were used as follows: TIB 122 (CD45), 68 KT3 (CD3), 69 YTA 3.1 (CD4), 70 and YTS 169.4 (CD8). 71 Cells were washed twice and then incubated with fluorescein (FITC) conjugated anti-rat IgG (Vector, Burlingame, CA, USA) for 45 min at 4°C. Samples were analyzed on a FACSort instrument using Cellquest v1.1 software (Becton Dickinson, Oxford, UK).
Anti-adenovirus antibody and anti-␤-galactosidase antibody assay Anti-adenovirus antibody and anti-␤-galactosidase antibody titres of serum were determined by enzyme-linked immunosorbent assay (ELISA). For the anti-adenovirus antibody assay, each well of a 96-well plate was coated overnight at 4°C with 50 l of 0.1 m NaHCO 3 buffer containing 2.5 × 10 6 p.f.u. of UV-irradiated AdLacZ (AdLacZ was exposed twice to a total of 1 joule of UV light). For the anti-␤-galactosidase antibody assay each well of a 96-well plate was coated overnight at 4°C with 50 l of 0.1 m NaHCO 3 buffer containing 0.05 mg ␤-galactosidase. The coating solution was flicked off and 200 l per well of the blocking buffer (PBS, 0.1% Tween-20) was added for 1 h at room temperature. Coated plates were washed four times with PBS. Tripling dilution of serum starting concentration 1/10; final serum dilution 1/21870 were added in duplicate serum in blocking buffer (50 l per well) and incubated for 2 h at room temperature. Wells were washed four times with PBS. 50 l per well of the solution of secondary antibody (10 l anti-mouse IgG Fc peroxidase conjugate; Sigma, in 5 ml blocking buffer) were incubated for 2 h at room temperature. Wells were rinsed four times with PBS. Finally, 50 l per well of the substrate solution (100 ml H 2 O, 1.5 g Na 2 HPO 4 , 1 g citric acid, 20 mg O-phenylenediamine dihydrochloride, 40 l H 2 O 2 ) was added to each well and substrate conversion was stopped by the addition of 50 l per well of 2.5 m H 2 SO 4 . The optical density (OD) was measured at 490 nm. Standard serum was included on each plate. OD was the average of two readings at each dilution and was subtracted from control well without adenovirus. The reference curve (OD versus concentration) was drawn by four parameter curve-fit. The concentration value at 1/2 maximum OD was calculated from reference curve. Titres were calculated as 100 × (concentration of sample serum at 1/2 maximum OD)/(concentration of standard serum at 1/2 maximum OD).
Statistical analysis
Data are expressed as means ± standard errors of the means (s.e.m.).
In FACS analysis, differences between the percentage of CD3 + , CD4 + , CD8 + T cells and the number of CD45 + cells in primed and unprimed C3H mice housed under conventional conditions at each time-point were tested by using test for equal variance (F test) followed by unpaired t test (Welch's or Student's t test). Differences in the antibody response to adenovirus and ␤-galactosidase between primed and unprimed C3H mice housed under conventional conditions were evaluated using test for equal variance (F test) followed by unpaired t test (Welch's or Student's t test). In a comparison between unprimed and primed C3H or C57BL/6 mice housed under either conventional or SPF conditions, differences of antibody responses to adenovirus and ␤-galactosidase among each group per time-point were tested by oneway ANOVA, followed by Scheffé's F test for multiple comparisons.
Immunocytochemistry
Ten-micron sections through the injection site and substantia nigra were prepared. After fixing in cold ethanol for 10 min, sections were treated with hydrogen peroxidase and blocked with 1.5% rabbit serum. Rat monoclonal antibodies were used as follows: TIB 122 (CD45), KT3 (CD3), YTA 3.1 (CD4), YTS 169.4 (CD8). Sections were incubated with primary antibodies overnight at room temperature. Horseradish peroxidase (HRP)-conjugated rabbit anti-rat IgG (Dako, High Wycombe, UK) absorbed with mouse serum was used as the secondary antibody and HRP was detected by using diaminobenzidine (Sigma, Poole, UK). Sections were counterstained with cresyl violet, dehydrated, cleared and mounted.
␤-Galactosidase staining
The animals were perfused intracardially with saline and Zamboni's fixative solutions. Cryostat sections of 75-m sections through the injection site and substantia nigra were cut. After washing with PBS, samples incubated with ␤-galactosidase solution per brain (7 ml PBS pH 7.2, 1 ml of 50 mm potassium ferricyanide, 1 ml of 50 mm potassium ferrocyanide, 0.4 ml of 50 mm MgCl 2 , 100 l of 1% solution of deoxycholic acid, 200 l of 1% solution of Nonident P-40, 10 mg ␤-galactosidase with 250 l DMSO) for 2 h at 32°C. After washing with PBS, samples were mounted on the gelatinised glass slides. Sections were counterstained with carminic acid, dehydrated, cleared and mounted.
